December 15, 2017. Organizations urge Zoetis to request voluntarily that the Food and Drug Administration (FDA) withdraw the approval for use in food-producing animals of Zoetis products that contain drugs in the polymyxin class.
Read More »On Health Policy
Letter to Ramaswamy at USDA NIFA on Funding for Research on Antibiotic Resistance
December 15, 2017. We ask that NIFA continue to support research into antibiotic resistance at least at the current levels and specifically include antibiotic resistance among the areas to be funded as part of the AFRI requests for applications for FY2018.
Read More »NCHR testimony at FDA about Clinical Trial Criteria for Interstitial Cystitis and Bladder Pain Syndrome
December 7, 2017. There is a need for new treatment options for interstitial cystitis and bladder pain syndrome (IC/BPS). These conditions have a range of causes and symptoms, and symptoms can be very similar to other conditions. This variation adds complexity to testing new treatments. To meet the needs of patients, the FDA must hold the sponsors’ clinical trials to a high standard that ensures safe and effective treatments.
Read More »NCHR Comments to HHS on Religious Exemptions and Contraceptives
December 5, 2017. We strongly oppose the IFR’s use of religious objections to undermine essential health care for millions of women in our country. The HHS must ensure the health of all our citizens by implementing policies based on sound medical and public health science. We urge that HHS bring evidenced-based practice into the forefront of health policies, as it has for decades.
Read More »NCHR Comments to CMS on 2019 Proposed Changes to Patient Protection and Affordable Care Act
November 22, 2017. We urge CMS to focus on strategies which address the health needs of all Americans and provide opportunities for more access to quality care. We are particularly concerned that changes to the Navigator program would reduce enrollment in ways that could be detrimental to the health of many Americans.
Read More »